Cv Therapeutics, Inc.

Gilead Sciences, Inc.

Elfaith O Elzein

Jeff A Zablocki

Venkata Poornapragnacharyulu Palle

Prabha N Ibrahim

Rao V Kalla

Xiaofen Li

Thao Perry

Dengming Xiao

Kevin D Shenk

Vaibhav Varkhedkar

Brent K Blackburn

Chris Richard Melville

Tim Marquart

Lisa Wang

Disclosed is a synthesis suitable for large scale manufacture of an A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.

[object Object]

Disclosed are novel Aadenosine receptor antagonists having the structure of Formula I or Formula II:The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

A2B adenosine receptor antagonists

Novel compounds of the general formula:and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of diabetes, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

Heteroaryl alkyl piperazine derivatives

Substituted alkylene diamine compounds

Orally active A1 adenosine receptor agonists

Growing community of inventors

Freemont, CA, United States of America

Elfaith O Elzein